Pharmacokinetics Study of Oral IXAZOMIB in Participants With Advanced Nonhematologic Malignancies or Lymphoma

NCT01454076 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

112

Enrollment

INDUSTRY

Sponsor class

Conditions

Nonhematologic Malignancies
Lymphoma

Interventions

DRUG: Ixazomib 2.5 mg
DRUG: Ixazomib 4 mg Capsule A
DRUG: Ixazomib 4 mg Capsule B
DRUG: Ketoconazole
DRUG: Rifampin
DRUG: Clarithromycin
DRUG: Ixazomib 4 mg Capsule B

Sponsor

Millennium Pharmaceuticals, Inc.